Stuart Jennings, MD
Nephrology · New Bern, NCNPI 1851566434
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,862 of the $39,658 with a category attached, or 62.7%. 34 manufacturers reported payments, led by Amgen at 46.6% of the total. 2025 is the largest year on record at $27,151, more than ten times the $319 reported in 2019. Among nephrology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $123.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$18K
- Calliditas Therapeutics US Inc.$13K
- Travere Therapeutics, Inc.$2K
- Nxstage Medical, Inc.$797
- Novartis$647
- AstraZeneca$505
- plus $4K from 28 others
What the payments were for
- Consulting fees$3,0388%
- Speaking & faculty fees$24,86263%
- Travel & lodging$4,79612%
- Food & beverage$6,66317%
- Education$3001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 70 | $18,473 |
| Calliditas Therapeutics US Inc. | 24 | $13,213 |
| Travere Therapeutics, Inc. | 14 | $2,224 |
| Nxstage Medical, Inc. | 12 | $797 |
| Novartis | 22 | $647 |
| AstraZeneca(2 entities) | 17 | $505 |
| Otsuka America Pharmaceutical, Inc. | 23 | $486 |
| Fresenius USA Marketing, Inc. | 15 | $393 |
| GE HealthCare | 1 | $347 |
| Bayer | 19 | $325 |
| Aurinia Pharma U.S., Inc. | 14 | $312 |
| Vifor Pharma, Inc. | 14 | $272 |
| GSK | 9 | $163 |
| Analog Devices Inc. | 1 | $140 |
| OPKO Pharmaceuticals, LLC | 9 | $135 |
| Boehringer Ingelheim | 7 | $124 |
| Novo Nordisk | 6 | $123 |
| Daiichi Sankyo Inc. | 7 | $110 |
| Mallinckrodt Hospital Products Inc. | 5 | $105 |
| Radiometer America, Inc | 1 | $98 |
| Shield Therapeutics Inc | 1 | $94 |
| Kyowa Kirin, Inc. | 4 | $86 |
| Akebia Therapeutics Inc | 6 | $83 |
| ZOLL Medical Corporation | 1 | $78 |
| Ardelyx, Inc. | 3 | $60 |
| Lilly USA, LLC | 3 | $56 |
| Alnylam Pharmaceuticals Inc. | 3 | $49 |
| BD | 1 | $39 |
| Pharmacosmos Therapeutics Inc. | 2 | $31 |
| Sanofi | 2 | $31 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$12,797
- Tavneos$12,677
- KRYSTEXXA$3,640
- VSCAN$347
- NXSTAGE SYSTEM ONE$336
- LUPKYNIS$122
- LIBERTY SELECT CYCLER$111
How this compares
$39,658 in reported general payments places this provider in the 95th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 632 | $421,984 |
| TavneosAvacopan | 11 | $183,226 |
| JardianceEmpagliflozin | 220 | $157,243 |
| KerendiaFinerenone | 91 | $68,014 |
| VeltassaPatiromer Calcium Sorbitex | 55 | $58,860 |
| VelphoroSucroferric Oxyhydroxide | 27 | $45,912 |
| LokelmaSodium Zirconium Cyclosilicate | 38 | $24,068 |
| OzempicSemaglutide | 20 | $23,298 |
| InvokanaCanagliflozin | 20 | $17,843 |
| Lanthanum Carbonate | 16 | $14,399 |
| RayaldeeCalcifediol | 13 | $13,531 |
| Sevelamer Carbonate | 48 | $8,632 |
| DapagliflozinDapagliflozin Propanediol | 18 | $8,367 |
| Repatha SureclickEvolocumab | 12 | $6,633 |
| Losartan Potassium | 609 | $4,853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $505 | $446,052670 claims |
| AmgenTavneos | $18,473 | $183,22611 claims |
| Boehringer IngelheimJardiance | $124 | $157,243220 claims |
| BayerKerendia | $325 | $68,01491 claims |
| Fresenius USA Marketing, Inc.Velphoro | $393 | $45,91227 claims |
| Novo NordiskOzempic | $123 | $23,29820 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $135 | $13,53113 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $14 | $31927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 366 nephrology providers in North Carolina.
Other nephrology in New Bern
- Nathan SaucierNew Bern$21K
- Gregory GreenwoodWinston-Salem$947K
- Michael EtomiCharlotte$212K
- William KendrickGreenville$125K
- Jason EckelCary$123K
- Raven VooraSanford$111K
- Nam VoAsheville$89K
- Jennifer StoddardPinehurst$77K
- Barry FreedmanWinston Salem$67K
- James McCabeWilmington$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.